Experimental Therapeutics Program

实验治疗计划

• 批准号: 10267041
• 负责人: MARIA R BAER
• 金额: $ 4.9万
• 依托单位: UNIVERSITY OF MARYLAND BALTIMORE
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-08-08 至 2026-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10267041
• 关键词: Address; Advisory Committees; Baltimore; Basic Science; Biometry; Cancer Center; Catchment Area; Cigarette; Clinic; Clinical; Clinical Investigator; Collaborations; Community Outreach; Comprehensive Cancer Center; County; Detection; Development; Diagnosis; Diagnostic; Direct Costs; Doctor of Medicine; Doctor of Philosophy; Early Diagnosis; Faculty; Flow Cytometry; Funding; Funding Agency; Genomics; Goals; Grant; Hematologic Neoplasms; Human; Image; In Vitro; Industry; Institutes; Investigational Therapies; Journals; Laboratories; Laboratory Study; Leadership; Malignant Neoplasms; Maryland; Measurement; Medical; Medical center; Mission; Molecular; Molecular Biology; Molecular Target; NCI Center for Cancer Research; Nanotechnology; Pathology; Patient-Focused Outcomes; Peer Review; Pharmacy Schools; Population Sciences; Positioning Attribute; Preclinical Testing; Public Health Schools; Publications; Radiation Oncology; Radiation Protection; Radiation therapy; Research; Research Personnel; Research Priority; School Dentistry; Services; Solid Neoplasm; Source; Suggestion; System; Testing; Therapeutic; Translating; Treatment outcome; Universities; acronyms; anticancer research; base; biobank; cancer therapy; college; community engagement; early phase clinical trial; hormone related cancer; improved; in vivo; innovation; liquid biopsy; medical schools; member; molecular carrier; neoplasm immunotherapy; new technology; novel; novel therapeutic intervention; novel therapeutics; pre-clinical; pre-clinical research; professor; programs; recruit; research clinical testing; response; structural biology; translational scientist; tumor immunology; virology

10.0 Abstract: Experimental Therapeutics (ET) Program The overarching goal of ET is to develop and test new therapies for solid tumors and hematologic malignancies based on innovative preclinical research. The emphasis is on bringing basic and preclinical discoveries from ET members to early-stage clinical testing and also on providing platforms for investigators in other programs to evaluate their findings in clinical settings. To achieve this mission, the program focuses on three specific aims: Aim 1: Target detection and measurement—Investigate diagnostic advances, including molecular early detection, liquid biopsy and imaging, to guide new treatment approaches and assessments of response; Aim 2: Molecular targeting: Development and preclinical and clinical testing—Investigate new cancer therapies based on novel molecular targets in in vitro and in vivo laboratory studies as well as early phase clinical trials; and Aim 3: Treatment delivery: Novel delivery strategies—Investigate the development of new technologies for therapy delivery, including molecular carriers, nanotechnology, and novel radiation therapy and radiation protection approaches. To achieve these three aims, members of ET are supported by extensive expertise available in other University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC) Programs to translate basic research findings to the clinic and by the availability of exceptional shared services. The ET Program has 56 members, including 31 full members and 25 associate members, who conduct cancer-focused research that receives $14.6 million direct cost annual funding ($19.4 million total), including $3.6 million (25%) from NCI and $4.1 million from other peer-reviewed sources. ET Program members receive $6.9 million annually from non-peer-reviewed funding sources. During this funding period, ET members authored 889 cancer-related publications, of which 22% resulted from intraprogrammatic, 21% from interprogrammatic, and 8% from intra- and interprogrammatic collaborations. Of the 889 publications, 72% include collaborations with external investigators, reflecting the high national impact of the ET Program. A high percentage of ET publications (14%) were in journals with an impact factor ≥10. Research efforts of ET members are supported by extensive use of all shared services. The ET Program collaborates with the other four UMGCCC research programs and facilitate community outreach and engagement (COE) to identify and address the cancer research priorities of the catchment area.

10.0翻译后摘要：实验治疗（ET）计划 ET的首要目标是开发和测试实体瘤和血液恶性肿瘤的新疗法 基于创新的临床前研究。重点是从ET中带来基础和临床前发现 成员进行早期临床试验，并为其他项目的研究人员提供平台， 在临床环境中评估他们的发现。为了实现这一使命，该方案侧重于三个具体目标： 目标1：靶点检测和测量-研究诊断进展，包括分子早期 检测、液体活检和成像，以指导新的治疗方法和反应评估;目标2： 分子靶向：开发、临床前和临床试验-研究新的癌症疗法 基于体外和体内实验室研究以及早期临床试验中的新型分子靶点; 目标3：治疗提供：新的提供战略-研究新技术的发展 用于治疗递送，包括分子载体、纳米技术和新型放射治疗和放射疗法 保护方法。为达致这三个目标，环境小组成员具备广泛的专业知识， 可在其他马里兰州大学玛琳和斯图尔特格林鲍姆综合癌症中心 （UMGCCC）将基础研究成果转化为临床研究成果的计划， 共享服务。ET计划有56个成员，包括31个正式成员和25个准成员， 开展以癌症为重点的研究，每年获得1460万美元的直接费用资助（总计1940万美元）， 其中360万美元（25%）来自NCI，410万美元来自其他同行评审来源。ET计划成员 每年从未经同行审查的供资来源获得690万美元。在这段时间里， 撰写了889篇癌症相关出版物，其中22%来自计划内，21%来自 方案间合作占8%，方案内和方案间合作占8%。在889份出版物中，72% 包括与外部调查人员的合作，反映了ET计划的高国家影响力。高 ET出版物的百分比（14%）在影响因子≥10的期刊中。ET成员的研究工作 通过广泛使用所有共享服务提供支持。ET计划与其他四个UMGCCC合作 研究计划，促进社区外展和参与（COE），以确定和解决癌症 流域研究的优先事项。